![Charles Link](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Link
Founder at
Syncromune, Inc.
Profile
Charles J.
Link was the founder of NewLink Genetics Corp.
(1999), serving as Chairman, Chief Executive & Scientific Officer from 2003 to 2019; Central Iowa Hospital Corp.
(1995), serving as Director from 1995 to 2003; and Syncromune, Inc. (2020), serving as Executive Chairman.
Current jobs include Director at NovaScan, Inc. (2020 - present), Director at ImmunSYS, Inc. (present), and Director at Viewpoint Molecular Targeting, Inc. (2021 - present).
Former jobs include Chairman & Chief Executive Officer at BioProtection Systems Corp.
(2005 - 2009), Independent Director at QSAM Biosciences, Inc. (2021 - 2024), and Chief Executive & Scientific Officer at Lumos Pharma, Inc. Education includes a doctorate from Stanford University School of Medicine.
Charles Link active positions
| Companies | Position | Start |
|---|---|---|
ImmunSYS, Inc.
 ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer immunotherapy products | Director/Board Member | - |
NovaScan, Inc.
 NovaScan, Inc. Medical SpecialtiesHealth Technology Manufactures cancer detection instrument | Director/Board Member | 2019-12-31 |
Viewpoint Molecular Targeting, Inc.
 Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Director/Board Member | 2021-05-17 |
Syncromune, Inc.
 Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops intratumoral immunotherapy platform for treating metastatic solid tumors | Founder | 2019-12-31 |
Former positions of Charles Link
| Companies | Position | End |
|---|---|---|
QSAM Biosciences, Inc.
 QSAM Biosciences, Inc. Chemicals: AgriculturalProcess Industries Manufactures compost | Director/Board Member | 2024-05-01 |
| LUMOS PHARMA, INC. | Chief Executive Officer | 2019-08-02 |
| LUMOS PHARMA, INC. | Chief Executive Officer | 2019-08-02 |
BioProtection Systems Corp.
 BioProtection Systems Corp. BiotechnologyHealth Technology Manufacturers biological products | Chairman | 2008-12-31 |
Central Iowa Hospital Corp. | Founder | 2002-12-31 |
Training of Charles Link
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
47
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops, and commercializes novel immunotherapeutic products for treatment of cancer | Health Technology |
BioProtection Systems Corp.
BioProtection Systems Corp. BiotechnologyHealth Technology Manufacturers biological products | Health Technology |
Central Iowa Hospital Corp. | |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
QSAM Biosciences, Inc.
QSAM Biosciences, Inc. Chemicals: AgriculturalProcess Industries Manufactures compost | Process Industries |
NovaScan, Inc.
NovaScan, Inc. Medical SpecialtiesHealth Technology Manufactures cancer detection instrument | Health Technology |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer immunotherapy products | Health Technology |
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops intratumoral immunotherapy platform for treating metastatic solid tumors | Health Technology |
- Stock Market
- Insiders
- Charles Link
